NCT05441904View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects.

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

March 29, 2021

Study Completion Date

March 29, 2021

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG

PXL770

A single dose of 500 and 750 mg was administered to each subject.

Trial Locations (1)

7EW

HMR, London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Poxel SA

INDUSTRY

NCT05441904 - Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. | Biotech Hunter | Biotech Hunter